Assessment of measurable residual disease (MRD) in multiple myeloma : a review of the data
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 Suppl 9 |
|---|---|
| Enthalten in: |
Clinical advances in hematology & oncology : H&O - 18 Suppl 9(2020), 3 vom: 01. März, Seite 2-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wolf, Jeffrey [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.09.2021 Date Revised 22.09.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM323989233 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323989233 | ||
| 003 | DE-627 | ||
| 005 | 20231225185345.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323989233 | ||
| 035 | |a (NLM)33843876 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wolf, Jeffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of measurable residual disease (MRD) in multiple myeloma |b a review of the data |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2021 | ||
| 500 | |a Date Revised 22.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical advances in hematology & oncology : H&O |d 2003 |g 18 Suppl 9(2020), 3 vom: 01. März, Seite 2-7 |w (DE-627)NLM157777022 |x 1543-0790 |7 nnns |
| 773 | 1 | 8 | |g volume:18 Suppl 9 |g year:2020 |g number:3 |g day:01 |g month:03 |g pages:2-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 Suppl 9 |j 2020 |e 3 |b 01 |c 03 |h 2-7 | ||